- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Antithrombotic Therapy
The Practical Cardiology™ Antithrombotic Therapy clinical resource center offers updates and information about the latest in the fields of antiplatelet and anticoagulation therapy. On this page you will find content related to FDA approvals and the latest information for preventing thrombosis in the form of articles, video interviews with leading experts, clinician-authored columns, and more.
PANTHER: P2Y12 Monotherapy Bests Aspirin for Secondary Prevention in Coronary Artery Disease
August 29, 2022
The PANTHER study, which was a meta-analysis of 7 RCTs comparing P2Y12 inhibitor monotherapy against aspirin for secondary prevention in CAD, suggests use of P2Y12 inhibitor monotherapy was associated with a 12% reduction in risk of the primary composite endpoint, with a 23% relative reduction in risk of myocardial infarction.
Milvexian Shows Promise for Preventing Stroke in Phase 2 Dose-Finding Trial
August 28, 2022
A phase 2 dose-finding trial presented at ESC Congress 22 suggests the use of milvexian could reduce the risk of ischemic stroke by up to 30% without a major increase in the risk of bleeding events in certain doses.
CHEST Releases New Guidance for Perioperative Management of Antithrombotic Therapy
August 12, 2022
On August 11, the American College of Chest Physicians (CHEST) released 44 new evidence-based recommendations in their new guidelines for perioperative management of antithrombotic therapy, which were published with the intention of replacing the 2012 guidelines on the subject.
Ticagrelor Use Varies Greatly Between Hospitals, Even Without Added Cost Considerations
July 15, 2022
After US-based data suggested cost as an inhibiting factor of ticagrelor use in older patients with ACS, an analysis of use in Canada details considerable variation in between-hospital levels of ticargelor, with use ranging from 0% to 83.6% of patients.
Studies Detail Thrombosis Risks Associated with Different COVID-19 Vaccines
June 27, 2022
Dr. Gregory Weiss provides perspective on a recent study detailing the risks of thrombosis observed with different COVID-19 vaccines among patients from a group of countries in Europe.
Rivaroxaban Bests Combination Therapy for Total Event, Mortality Risk in Stable CAD with AFib
June 16, 2022
A secondary analysis of the AFIRE trial provides further detail on the reduction in event risk and mortality associated with rivaroxaban monotherapy compared to combination therapy in patients with atrial fibrillation and stable coronary artery disease.
AUGUSTUS Results Consistent, Regardless of Stroke History, Study Finds
May 25, 2022
A post hoc analysis of the AUGUSTUS trial provides an overview of the effects of various antithrombotic regimens after ACS or PCI in patients with AFib and a history of stroke, TIA, or thromboembolism.
Clopidogrel Tops Aspirin for Long-Term Antiplatelet Therapy After PCI in High-Risk Patients
May 20, 2022
An analysis of data from the Fuwai PCI registry details the incidence of adverse events and risk of bleeding associated with clopidogrel monotherapy versus aspirin monotherapy 12 months post-PCI in high-risk patients.
Phase 2b Trial of Bentracimab Supports Use in Older Patients
April 06, 2022
Data from a phase 2b trial of bentracimab presented by Deepak Bhatt, MD, MPH, at ACC.22 demonstrates it the ability for reversing antiplatelet effects in an older population.